Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 1
2021 1
2022 2
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R. Wang C, et al. Among authors: du chatinier a. Nature. 2019 Oct;574(7777):268-272. doi: 10.1038/s41586-019-1607-3. Epub 2019 Oct 2. Nature. 2019. PMID: 31578521 Free PMC article.
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1.
Cornel AM, van der Sman L, van Dinter JT, Arrabito M, Dunnebach E, van Hoesel M, Kluiver TA, Lopes AP, Dautzenberg NMM, Dekker L, van Rijn JM, van den Beemt DAMH, Buhl JL, du Chatinier A, Barneh F, Lu Y, Lo Nigro L, Krippner-Heidenreich A, Sebestyén Z, Kuball J, Hulleman E, Drost J, van Heesch S, Heidenreich OT, Peng WC, Nierkens S. Cornel AM, et al. Among authors: du chatinier a. J Immunother Cancer. 2024 Mar 21;12(3):e007538. doi: 10.1136/jitc-2023-007538. J Immunother Cancer. 2024. PMID: 38519054 Free PMC article.
Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors.
Metselaar DS, Meel MH, Goulding JR, du Chatinier A, Rigamonti L, Waranecki P, Geisemeyer N, de Gooijer MC, Breur M, Koster J, Veldhuijzen van Zanten SEM, Bugiani M, Franke NE, Reddy A, Wesseling P, Kaspers GJL, Hulleman E. Metselaar DS, et al. Among authors: du chatinier a. Cell Rep Med. 2024 Sep 17;5(9):101700. doi: 10.1016/j.xcrm.2024.101700. Epub 2024 Aug 28. Cell Rep Med. 2024. PMID: 39208799 Free PMC article.
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mulero-Sánchez A, Ramirez CFA, du Chatinier A, Wang H, Koomen SJI, Song JY, de Groot MHP, Lieftink C, Bosma A, Burylo A, van Tellingen O, Beijersbergen RL, Wang C, Akkari L, Bernards R, Mainardi S. Mulero-Sánchez A, et al. Among authors: du chatinier a. Mol Oncol. 2023 Jun;17(6):964-980. doi: 10.1002/1878-0261.13377. Epub 2023 Feb 9. Mol Oncol. 2023. PMID: 36650715 Free PMC article.